Neoadjuvant immunotherapy of locoregionally advanced solid tumors
Definitive management of locoregionally advanced solid tumors presents a major challenge and often consists of a combination of surgical, radiotherapeutic and systemic therapy approaches. Upfront surgical treatment with or without adjuvant radiotherapy carries the risks of significant morbidities an...
Main Authors: | John Wright, Patrick M Forde, Robert L Ferris, Ahmad A Tarhini, Kathleen N Moore, Jennifer R Eads, Valerie Tatard-Leitman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-08-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/8/e005036.full |
Similar Items
-
The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis
by: Ángela Bella, et al.
Published: (2023-12-01) -
Advances in Cancer Immunotherapy in Solid Tumors
by: Smitha Menon, et al.
Published: (2016-11-01) -
Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy
by: Hsu-Huan Chou, et al.
Published: (2019-02-01) -
Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
by: Yuan Xu, et al.
Published: (2023-06-01) -
Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors
by: Cody R. Criss, et al.
Published: (2023-07-01)